Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis

ConclusionsPD-1 blockade plus lenvatinib is effective and safe in routine practice. PD-L1 expression and CA19-9 level appear to predict the treatment efficacy.IDH1 mutations might indicate a better treatment response.Clinical trial registration: NCT03892577.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research